NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free TCRX Stock Alerts $7.26 +0.14 (+1.97%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$7.02▼$7.5550-Day Range$5.73▼$8.3052-Week Range$1.62▼$9.00Volume208,208 shsAverage Volume187,514 shsMarket Capitalization$347.61 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get TScan Therapeutics alerts: Email Address TScan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.2% Upside$12.50 Price TargetShort InterestHealthy0.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.03) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector642nd out of 910 stocksBiological Products, Except Diagnostic Industry108th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.60% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 16.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRX. Previous Next 1.8 News and Social Media Coverage News SentimentTScan Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.27% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.03) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About TScan Therapeutics Stock (NASDAQ:TCRX)TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More TCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRX Stock News HeadlinesApril 23, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On TScan TherapeuticsApril 22, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 23, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 22, 2024 | seekingalpha.comSimplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And BeyondApril 20, 2024 | americanbankingnews.comResearch Analysts Set Expectations for TScan Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TCRX)April 19, 2024 | globenewswire.comTScan Therapeutics Announces Closing of Upsized Public OfferingApril 19, 2024 | americanbankingnews.comBrokers Set Expectations for TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX)April 19, 2024 | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by WedbushApril 23, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 18, 2024 | investing.comTScan launches $125 million public stock offeringApril 17, 2024 | finanznachrichten.deTScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesApril 17, 2024 | markets.businessinsider.comTScan Therapeutics Announces Pricing Of Public Offering - Quick FactsApril 17, 2024 | finance.yahoo.comTScan Therapeutics Announces Pricing of Upsized $150 Million Public OfferingApril 16, 2024 | finance.yahoo.comTScan Therapeutics Announces Launch of $125 Million Proposed Public OfferingApril 16, 2024 | globenewswire.comTScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesApril 8, 2024 | markets.businessinsider.comTScan Therapeutics Appoints Chrystal Louis As Chief Medical Officer - Quick FactsApril 8, 2024 | markets.businessinsider.comTScan Therapeutics Appoints Louis As CMOApril 8, 2024 | finance.yahoo.comTScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical OfficerApril 8, 2024 | globenewswire.comTScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.April 2, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | finance.yahoo.comHedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%March 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 11, 2024 | markets.businessinsider.comPositive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial PositionMarch 7, 2024 | markets.businessinsider.comStrong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial HealthMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 ResultsMarch 7, 2024 | finance.yahoo.comTScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical PipelineMarch 6, 2024 | benzinga.comTScan Therapeutics: Q4 Earnings InsightsSee More Headlines Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees154Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside+72.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,220,000.00 Net Margins-423.86% Pretax Margin-423.86% Return on Equity-60.65% Return on Assets-33.86% Debt Debt-to-Equity Ratio0.18 Current Ratio6.51 Quick Ratio6.51 Sales & Book Value Annual Sales$21.05 million Price / Sales16.51 Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book2.30Miscellaneous Outstanding Shares47,880,000Free Float43,922,000Market Cap$347.61 million OptionableNot Optionable Beta0.90 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Gavin MacBeath Ph.D. (Age 54)CEO & Director Comp: $650.17kDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Jason A. Amello (Age 56)Chief Financial Officer Mr. Leiden Dworak M.B.A.Principal Accounting Officer & TreasurerDr. Justin McCue Ph.D.Chief Technology OfficerMs. Ann HargravesSenior Vice President of Human ResourcesDr. Shrikanta Chattopadhyay M.D.Senior VP & Head of Translational MedicineMore ExecutivesKey CompetitorsAnavex Life SciencesNASDAQ:AVXLMeiraGTxNASDAQ:MGTXTenaya TherapeuticsNASDAQ:TNYASOPHiA GENETICSNASDAQ:SOPHAura BiosciencesNASDAQ:AURAView All CompetitorsInsiders & InstitutionsCannon Global Investment Management LLCBought 17,500 shares on 4/17/2024Ownership: 0.037%Pale Fire Capital SEBought 4,998 shares on 2/14/2024Ownership: 0.045%Letko Brosseau & Associates Inc.Sold 11,700 shares on 2/12/2024Ownership: 0.043%abrdn plcBought 200,000 shares on 1/31/2024Ownership: 0.418%Timothy J BarberichBought 28,830 shares on 12/18/2023Total: $140,978.70 ($4.89/share)View All Insider TransactionsView All Institutional Transactions TCRX Stock Analysis - Frequently Asked Questions Should I buy or sell TScan Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares. View TCRX analyst ratings or view top-rated stocks. What is TScan Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price targets for TScan Therapeutics' stock. Their TCRX share price targets range from $10.00 to $15.00. On average, they anticipate the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price. View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts. How have TCRX shares performed in 2024? TScan Therapeutics' stock was trading at $5.83 at the beginning of 2024. Since then, TCRX stock has increased by 24.5% and is now trading at $7.26. View the best growth stocks for 2024 here. When is TScan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCRX earnings forecast. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) released its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 60.65% and a negative net margin of 423.86%. What ETF holds TScan Therapeutics' stock? Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 7.98% of its portfolio. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $100 million in an IPO on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are TScan Therapeutics' major shareholders? TScan Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Barbara Klencke, Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
